RxDoctor Payments Data

Ashley Gardner, NP

Nurse Practitioner · Saginaw, MINPI 1467902825

Payments from drug & device makers

$450in general payments, 2019–2025

Across 21 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$91
  • Organon$75
  • Exact Sciences$50
  • AstraZeneca$48
  • GSK$29
  • Xeris Pharmaceuticals, Inc.$24
  • plus $132 from 7 others

What the payments were for

  • Food & beverage$450100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$450 in reported general payments places this provider in the 70th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$683
Medicare patients
25
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide85$98,460
JardianceEmpagliflozin80$75,548
TrulicityDulaglutide64$70,121
EliquisApixaban85$63,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$60,700
OzempicSemaglutide39$60,010
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$33,078
FarxigaDapagliflozin Propanediol21$30,401
LinzessLinaclotide39$21,888
TradjentaLinagliptin16$18,413
Synjardy XrEmpagliflozin/Metformin Hcl13$15,482
Breo ElliptaFluticasone/Vilanterol30$14,663
Trijardy XrEmpaglifloz/Linaglip/Metformin11$13,962
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$12,424
Sucralfate22$7,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$21$168,580149 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$29$81,595133 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$48$68,40375 claims
PfizerEliquis$14$63,08085 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →